AstraZeneca Advances Baxdrostat in Phase III Trials for Uncontrolled and Resistant Hypertension
核心洞察
AstraZeneca is conducting two Phase III trials evaluating baxdrostat, a novel antihypertensive agent, in approximately 512 participants with uncontrolled or resistant hypertension (搜索).
The first study (D6970C00008) compares 1 mg and 2 mg baxdrostat doses against placebo in 300 participants with hypertension (搜索) despite stable dual or triple therapy.
The second study (D6970C00009) focuses specifically on resistant hypertension (搜索), testing 2 mg baxdrostat versus placebo in 212 participants using 24-hour ambulatory blood pressure monitoring.
AstraZeneca is advancing baxdrostat through two pivotal Phase III clinical trials targeting patients with uncontrolled and resistant hypertension (搜索), conditions that affect millions worldwide and represent significant therapeutic challenges despite existing treatment options.
Dual Phase III Program Design
The pharmaceutical company has initiated two complementary randomized, double-blind, placebo-controlled studies designed to evaluate baxdrostat's efficacy across different hypertension (搜索) populations. Study D6970C00008 will enroll approximately 300 participants aged 18 years and older, while study D6970C00009 will include 212 participants with resistant hypertension (搜索).
Both trials employ rigorous inclusion criteria, requiring participants to have systolic blood pressure of 140 mmHg or higher at screening despite stable antihypertensive regimens. The studies specifically target patients whose blood pressure remains uncontrolled despite adherence to evidence-based combination therapy including diuretics.
Primary Efficacy Endpoints and Methodology
Study D6970C00008 focuses on office-based blood pressure measurements, with the primary objective comparing systolic blood pressure change from baseline at Week 12 between participants receiving 1 mg or 2 mg baxdrostat tablets versus placebo. This study addresses both uncontrolled hypertension (搜索), defined as elevated blood pressure despite two antihypertensive agents including a diuretic, and resistant hypertension (搜索) requiring three or more agents.
The companion study D6970C00009 employs 24-hour ambulatory blood pressure monitoring (ABPM) as its primary endpoint, evaluating the effect of 2 mg baxdrostat on average ambulatory systolic blood pressure reduction. This approach provides comprehensive assessment of blood pressure control throughout the day-night cycle, offering more robust efficacy data than office measurements alone.
Target Patient Population
The trials specifically address resistant hypertension (搜索), defined as blood pressure targets not being achieved despite use of at least three antihypertensive agents of different classes at maximum tolerated doses, with one being a diuretic. For study D6970C00009, participants must demonstrate seated systolic blood pressure of 140 mmHg or higher at screening and mean ambulatory systolic blood pressure of 130 mmHg or higher at baseline.
This patient population represents a significant unmet medical need, as resistant hypertension (搜索) affects individuals who have failed to achieve blood pressure control despite optimal medical therapy. The condition carries increased cardiovascular risk and requires novel therapeutic approaches beyond conventional antihypertensive combinations.
Clinical Development Strategy
The parallel study design allows AstraZeneca to evaluate baxdrostat across the spectrum of difficult-to-treat hypertension (搜索) while employing different measurement methodologies. The dose-ranging component in study D6970C00008 will provide crucial data for optimal dosing recommendations, comparing both 1 mg and 2 mg daily doses against placebo.
Both studies utilize once-daily oral administration, potentially offering improved patient compliance compared to multiple-daily-dose regimens. The 12-week treatment duration in the primary study provides sufficient time to assess sustained blood pressure reduction while maintaining feasible trial timelines for regulatory submission.
Regulatory and Commercial Implications
These Phase III trials represent the final efficacy studies required for regulatory approval, positioning baxdrostat as a potential new treatment option for patients with uncontrolled and resistant hypertension (搜索). The dual-study approach strengthens the regulatory package by demonstrating efficacy across different patient populations and measurement methodologies.
Success in these trials could establish baxdrostat as an important addition to the antihypertensive armamentarium, particularly for patients who have exhausted conventional treatment options. The focus on resistant hypertension (搜索) addresses a well-defined patient population with clear unmet medical needs and established clinical guidelines.